Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
BOSTON, May 30, 2017 -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced it will webcast its corporate presentation at the Jefferies 2017 Healthcare Conference in New York City on Tuesday, June 6, 2017 at 1:30 p.m. Eastern Time.
A live audio webcast of the presentation will be accessible from Keryx’s website at http://investors.keryx.com within the Investor Relations section under “webcasts and presentations.” An archived version of the webcast will be available for at least 15 days following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts, is a commercial stage company focused on bringing innovative medicines to people with renal disease. Keryx developed and commercializes Auryxia® (ferric citrate) in the U.S. Ferric citrate is marketed as Riona® by Keryx’s Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex). Keryx has programs underway to leverage its development and commercial infrastructure, including potentially expanding the indication of Auryxia and in-licensing medicines for renal disease. For more information about Keryx, please visit www.keryx.com.
KERYX BIOPHARMACEUTICALS CONTACT: Lora Pike Senior Director, Investor Relations & Corporate Communications T: 617-466-3511 [email protected]
